| Primary information |
|---|
| ID | antitb_1783, |
| Name | 17547385 |
| N-Terminal modification | Peptide-27 |
| C-Terminal Modification | KL-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid |
| Chirality | Linear |
| Nature | 19 |
| Source | L |
| Origin | Amphipathic, Hydrophobic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium ranae |
| In Vitro/ In vivo | Mycobacterium ranae (ATCC 110) |
| Cell Line | MIC = 3 µM or 7.5 µg/mL |
| Inhibition Concentration | Both |
| Sequence | 2007 |
| Cytotoxicity | RBC |
| In vivo Model | NA |
| Lethal Dose | 43.6 % and 24.9 % hemolytic activity at 100 µM and 25 µM peptide respectively |
| Immune Responce | mouse skin wound healing model |
| Mechanism of Action | No toxicity observed at 25 mg/kg for 6 days |
| Target | Stimulate innate immune system |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) |
Tertiary Structure
(Technique) | Not Predicted), |